|NASDAQ: ATRC||Healthcare / Medical Devices & Instruments / USA|
|40.83||+2.85||+7.50%||Vol 808.98K||1Y Perf -39.93%|
|Mar 24th, 2023 16:00 DELAYED|
|- -||- -%|
|Target Price||59.33||Analyst Rating||Strong Buy 1.43|
|Potential %||45.31||Finscreener Ranking||★★★ 49.85|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||★★★+ 52.54|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||★★+ 49.22|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||— -|
|Price Range Ratio 52W %||23.07||Earnings Rating||Sell|
|Market Cap||1.90B||Earnings Date||2nd May 2023|
Today's Price Range
5 Year PE Ratio Range
|Mngmt Effectiveness||Value||Industry||S&P 500||US Markets|
ROE (5Y Avg)
ROE last 12 Months
ROA (5Y Avg)
ROA last 12 Months
ROC (5Y Avg)
ROC last 12 Months
Return on invested Capital Q
Return on invested Capital Y
|Valuation||Value||Industry||S&P 500||US Markets|
|Financial Strength||Value||Industry||S&P 500||US Markets|
|Profitability||Value||Industry||S&P 500||US Markets|
|Revenue||Value||Industry||S&P 500||US Markets|
|Dividends||Value||Industry||S&P 500||US Markets|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||2nd May 2023|
|Estimated EPS Next Report||-0.34|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||412.92K|
|Avg. Monthly Volume||356.42K|
|Avg. Quarterly Volume||326.47K|
AtriCure Inc. (NASDAQ: ATRC) stock closed at 40.83 per share at the end of the most recent trading day (a 7.5% change compared to the prior day closing price) with a volume of 808.98K shares and market capitalization of 1.90B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 730 people. AtriCure Inc. CEO is Michael H. Carrel.
The one-year performance of AtriCure Inc. stock is -39.93%, while year-to-date (YTD) performance is -8%. ATRC stock has a five-year performance of 103.74%. Its 52-week range is between 32.51 and 68.58, which gives ATRC stock a 52-week price range ratio of 23.07%
AtriCure Inc. currently has a PE ratio of -37.50, a price-to-book (PB) ratio of 4.72, a price-to-sale (PS) ratio of 8.42, a price to cashflow ratio of 255.30, a PEG ratio of 2.32, a ROA of -9.38%, a ROC of -9.89% and a ROE of -11.94%. The company’s profit margin is -17.45%, its EBITDA margin is -12.60%, and its revenue ttm is $242.35 Million , which makes it $5.21 revenue per share.
Of the last four earnings reports from AtriCure Inc., there were 1 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.34 for the next earnings report. AtriCure Inc.’s next earnings report date is 02nd May 2023.
The consensus rating of Wall Street analysts for AtriCure Inc. is Strong Buy (1.43), with a target price of $59.33, which is +45.31% compared to the current price. The earnings rating for AtriCure Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
AtriCure Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
AtriCure Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 9.83, ATR14 : 1.78, CCI20 : 109.52, Chaikin Money Flow : 0.00, MACD : -0.52, Money Flow Index : 59.54, ROC : 7.45, RSI : 55.30, STOCH (14,3) : 96.08, STOCH RSI : 1.00, UO : 49.89, Williams %R : -3.92), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of AtriCure Inc. in the last 12-months were: Mark A. Collar (Option Excercise at a value of $93 000), Robert S. White (Option Excercise at a value of $296 800), Tonya Austin (Sold 3 485 shares of value $154 104 ), Vinayak Doraiswamy (Sold 4 983 shares of value $229 168 )
|Analyst Ratings||Current||1 M ago||3 M ago|
|Summary Rating||Strong Buy||Strong Buy||Strong Buy|
AtriCure Inc an atrial fibrillation solutions company that provides products, professional education, and support for clinical science to reduce the economic and social burden of atrial fibrillation. Its products line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. The company also offer a variety of minimally invasive ablation devices and access tools to facilitate the growing trend in less invasive cardiac and thoracic surgery. Geographically, it generates a majority of its revenue from the United States.
CEO: Michael H. Carrel
Telephone: +1 513 755-4100
Address: 7555 Innovation Way, Mason 45040, OH, US
Number of employees: 730
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.